InGSA:在CNN中整合普遍的自我注意力,用于阿尔茨海默氏症疾病分类
Faisal Binzagr1, Anas W Abulfaraj2
1Department of Computer Science, King Abdulaziz University, Rabigh, Saudi Arabia.
Frontiers in artificial intelligence
|March 27, 2025
概括
这项研究介绍了InGSA,这是一种新的深度学习模型,用于从MRI扫描中早期诊断阿尔茨海默病. 它通过增强图像对比度和使用通用的自我注意力机制来有效地识别疾病模式来提高准确性.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知功能.
- 早期诊断AD对于症状管理至关重要,但传统方法面临局限性.
- 现有的机器学习和卷积神经网络 (CNN) 方法因复杂的特征提取和特异性问题而难以从MRI扫描中识别AD.
研究的目的:
- 开发一个先进的深度学习框架,使用MRI数据准确的多类阿尔茨海默病分类.
- 为了克服AD诊断中传统特征提取方法的局限性.
- 引入一种新的对比增强技术和CNN转换器模型,以改进AD检测.
主要方法:
- 在MRI扫描中实施降低雾的局部-全球 (HRLG) 对比增强方法.
- 基于预训练的InceptionV3架构开发了一个名为InGSA的全球CNN变压器模型.
- 在InGSA模型中集成一个通用的自我注意 (GSA) 块,以捕捉空间和通道智能的特征交互,并抑制噪音.
主要成果:
- 拟议的InGSA模型在两个基准数据集上的多类AD分类中表现出卓越的性能.
- GSA模块有效地捕获了AD相关信息的复杂细节,同时减轻了噪音.
- 使用各种预先训练的网络进行的评估证实了GSA机制的有效性.
结论:
- 结合HRLG对比度增强和GSA模块的InGSA框架,在MRI诊断阿尔茨海默氏病方面取得了重大进展.
- 这种深度学习方法克服了与传统方法相关的挑战,提供了更高的特异性和效率.
- 这些发现表明了开发更准确,更可靠的早期AD检测工具的有希望的方向.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.8K
06:19Integration of Animal Behavioral Assessment and Convolutional Neural Network to Study Wasabi-Alcohol Taste-Smell Interaction
Published on: August 16, 2024
354
相关概念视频
Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
